Clinical trials: Psychotic Episode
Schizophrenia, Bipolar Disorder
Indicated Prevention of Psychotic Disorders With Low-dose Lithium
This study investigates the neuroprotective properties of low-dose lithium in young individuals at ultra-high risk of developping a first psychotic episode.
- Conditions
- Schizophrenia, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT00202306
- Testing
- lithium carbonate
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Melbourne Health
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Episode, Psychological Trauma
A Rater-blinded RCT to Compare Effectiveness of EMDR vs TAU in Patients With First Episode Psychosis and History of Psychological Trauma
The main objective of this project is to analyze whether EMDR therapy, as an adjuvant to usual treatment, is effective in reducing post-traumatic stress and psychotic/affective symptoms in patients with a FEP and comorbid…
- Trial name
- NCT03991377
- Testing
- Eye movement desensitization and reprocessing therapy, Treatment as usual
- Where
- Spain
- Volunteers
- 71 people
- Sponsor
- Parc de Salut Mar
Impaired Insight
Study on Deep Transcranial Magnetic Stimulation for Enhancing Insight
Impaired insight is a key factor in the conversion of high-risk individuals to schizophrenia, but there is a lack of targeted interventions.
- Trial name
- NCT06831877
- Testing
- active-dTMS
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Psychosis, First Episode Psychosis
Feasibility of an Early Detection Program for Early Psychosis on a College Campus
The objective of the proposed study is to determine the feasibility of an Early Detection program that aims to: (i) identify college students at clinical high risk (CHR) of psychosis or with first episode psychosis (FEP), and…
- Conditions
- Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
- Trial name
- NCT03983421
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2 (NCT02305823)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
First Episode Psychosis
Efficacy and Safety With Ziprasidone in First-episode Psychosis
The aim of the study is to investigate the efficacy and safety of ziprasidone in patients with first episode psychosis.
- Trial name
- NCT01157559
- Testing
- Ziprasidone
- Where
- 3 sites in South Korea
- Volunteers
- 27 people
- Sponsor
- Chonbuk National University Hospital
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
First-Episode Psychosis, Bipolar Disorder
Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI
Significant changes in brain morphology are observed in people with first-episode psychosis. Studies have shown that total brain volume and particular brain structures are decreased in people with psychosis disorders.
- Trial name
- CARB (NCT02334904)
- Testing
- Aripiprazole, Risperidone
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
First Episode Psychosis
Artificial Intelligence to Measure Adherence to Oral Medication
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
- Trial name
- NCT04046497
- Testing
- Smartphone App, Usual Care
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Northwell Health
First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication
The goal of this project is to investigate whether a systematic screening approach enhanced by an innovative model of communicating information about psychosis and treatment options to patients and families (ComPsych) can reduce…
- Trial name
- EaSIE (NCT05509998)
- Testing
- Screening Method (SM), Screening and Communication Method (SCM)
- Where
- United States
- Volunteers
- 912 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Diet, Healthy, Psychotic Disorders
Weight Management Program for Patients With First Episode Psychosis
Severe mental illnesses (SMI), such as schizophrenia, are associated with increased morbidity and mortality in large part due to obesity and concomitant metabolic disorders.
- Trial name
- NCT05207982
- Testing
- Family Based weight management program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- State University of New York at Buffalo
First-episode Psychosis, Cannabis Abuse
COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE
General objective: To assess the effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment +…
- Trial name
- NCT02319746
- Testing
- Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse, Psychoeducation
- Where
- Spain
- Volunteers
- 88 people
- Sponsor
- Basque Health Service
Psychosis
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
The purpose of this study is determine the minimal effective dose and the impact on: 1. treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients experiencing the first psychotic episode 2.
- Trial name
- NCT00449397
- Testing
- Quetiapine Fumarate
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Schizophrenia, Psychotic Disorders
Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings…
- Trial name
- PSYDEV (NCT04370730)
- Testing
- clinical, neuroimaging and DNA assessments
- Where
- 6 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psychosis, First Episode Psychosis
Stratification and Treatment in Early Psychosis Study - ENHANCE
The purpose of this study is: To investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD) to the existing treatment, compared to placebo, in participants with a first episode of…
- Conditions
- Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
- Trial name
- STEP-ENHANCE (NCT06778564)
- Testing
- CBD 100 mg/mL Oral Solution
- Where
- 17 sites in Austria, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Schizophrenia, Schizoaffective Disorder
Optimizing Response in Psychosis Study
The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
- Trial name
- ORP (NCT00314327)
- Testing
- long-acting injectable risperidone
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwell Health
Bipolar Disorders, Mood Disorders
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.
- Conditions
- Bipolar Disorders, Mood Disorders, Affective Disorders, Psychotic
- Trial name
- NCT00240721
- Testing
- topiramate
- Volunteers
- 363 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Smoking, Psychosis
A Usability Study of a Smoking Cessation Decision Aid in People With a Recent First Episode of Psychosis
The investigators propose to recruit patients who have experienced a recent first episode of psychosis who have a chart diagnosis of Schizophrenia, Schizophrenifom, Schizoaffective Disorder, Psychosis NOS, or Bipolar I Disorder…
- Trial name
- NCT01399112
- Testing
- Web-based computer program
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Northwell Health